- increased T cell number / IMPC
- hyperactivity / IMPC
- decreased hemoglobin content / IMPC
- abnormal glucose homeostasis / IMPC
- thrombocytosis / IMPC
- decreased hematocrit / IMPC
- decreased circulating cholesterol level / IMPC
- decreased IgG3 level / IMPC
- decreased mature B cell number / IMPC
- decreased circulating free fatty acids level / IMPC
- increased IgM level / IMPC
- increased IgG1 level / IMPC
- decreased circulating triglyceride level / IMPC
- decreased bone mineral density / IMPC
- increased IgG2b level / IMPC
- decreased erythrocyte cell number / IMPC
B10.Cg-Plcg2tm1Jni H2d Tg(BCL2)36Wehi Tg(Igh2k3-83)1Nemz/H
Status | Available to order |
EMMA ID | EM:01892 |
International strain name | B10.Cg-Plcg2tm1Jni H2d Tg(BCL2)36Wehi Tg(Igh2k3-83)1Nemz/H |
Alternative name | Plcg2 |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | Plcg2tm1Jni, H2d, Tg(BCL2)36Wehi, Tg(Igh2k3-83)1Nemz |
Gene/Transgene symbol | Plcg2, H2, Tg(BCL2)36Wehi, Tg(Igh2 |
Information from provider
Provider | Martin Turner |
Provider affiliation | The Babraham Institute, Babraham, Cambridge, CB2 4PB |
Genetic information | These mice have a null mutation in Plcg2 and display defects in B-lymphocyte function. They also contain a transgene encoding a specific B-cell receptor and a transgene that directs expression of the anti-apoptotic protein Bcl2 to both B- and T-cells. |
Phenotypic information | Defects in B-lymphocyte development. High incidence of perinatal lethality. Homozygotes are infertile. |
References | None available |
Information from EMMA
Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- PLCG2-associated antibody deficiency and immune dysregulation / Orphanet_300359
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation / Orphanet_324530
IMPC phenotypes (gene matching)
MGI phenotypes (allele matching)
- decreased hematocrit / MGI
- abnormal liver physiology / MGI
- abnormal T cell differentiation / MGI
- abnormal cytokine secretion / MGI
- increased autoantibody level / MGI
- decreased susceptibility to parasitic infection / MGI
- arrested B cell differentiation / MGI
- abnormal dendritic cell physiology / MGI
- abnormal B cell physiology / MGI
- decreased susceptibility to induced arthritis / MGI
- decreased B cell proliferation / MGI
- abnormal dendritic cell morphology / MGI
- decreased follicular B cell number / MGI
- increased pro-B cell number / MGI
- decreased mature B cell number / MGI
- increased B cell apoptosis / MGI
- decreased platelet aggregation / MGI
- increased transitional stage T2 B cell number / MGI
- abnormal dendritic cell chemotaxis / MGI
- abnormal trabecular bone morphology / MGI
- abnormal B cell differentiation / MGI
- increased susceptibility to viral infection / MGI
- increased pre-B cell number / MGI
- decreased osteoclast cell number / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- increased B cell proliferation / MGI
- abnormal osteoclast differentiation / MGI
- decreased interferon-gamma secretion / MGI
- increased trabecular bone thickness / MGI
- increased trabecular bone volume / MGI
MGI phenotypes (gene matching)
- decreased hematocrit / MGI
- abnormal liver physiology / MGI
- abnormal T cell differentiation / MGI
- increased susceptibility to bacterial infection / MGI
- abnormal immunoglobulin level / MGI
- increased IgM level / MGI
- abnormal cytokine secretion / MGI
- thyroid inflammation / MGI
- increased autoantibody level / MGI
- insulitis / MGI
- increased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to parasitic infection / MGI
- immune system phenotype / MGI
- periinsulitis / MGI
- abnormal T cell number / MGI
- decreased CD4-positive, alpha beta T cell number / MGI
- increased CD8-positive, alpha-beta T cell number / MGI
- decreased IgG1 level / MGI
- decreased IgG2a level / MGI
- increased physiological sensitivity to xenobiotic / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- abnormal trabecular bone morphology / MGI
- abnormal foot pad morphology / MGI
- spleen hyperplasia / MGI
- dermatitis / MGI
- internal hemorrhage / MGI
- abnormal humoral immune response / MGI
- arrested B cell differentiation / MGI
- decreased IgM level / MGI
- abnormal inflammatory response / MGI
- abnormal lymphatic vessel morphology / MGI
- premature death / MGI
- abnormal B cell differentiation / MGI
- abnormal dendritic cell physiology / MGI
- increased susceptibility to viral infection / MGI
- abnormal B cell physiology / MGI
- chronic inflammation / MGI
- glomerulonephritis / MGI
- increased pre-B cell number / MGI
- decreased susceptibility to induced arthritis / MGI
- osteoarthritis / MGI
- decreased osteoclast cell number / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- decreased B cell proliferation / MGI
- increased B cell proliferation / MGI
- immune system phenotype / MGI
- abnormal dendritic cell morphology / MGI
- decreased B-1a cell number / MGI
- decreased follicular B cell number / MGI
- increased pro-B cell number / MGI
- decreased transitional stage B cell number / MGI
- decreased B-2 B cell number / MGI
- decreased mature B cell number / MGI
- abnormal osteoclast differentiation / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-gamma secretion / MGI
- increased B cell apoptosis / MGI
- increased trabecular bone thickness / MGI
- decreased platelet aggregation / MGI
- increased transitional stage T2 B cell number / MGI
- abnormal dendritic cell chemotaxis / MGI
- abnormal NK cell physiology / MGI
- increased trabecular bone volume / MGI
- chylous ascites / MGI
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).